Epigenomics AG

EANS-Adhoc: Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act): Epigenomics AG Announces Capital Increase


--------------------------------------------------------------------------------
  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
Restructuring & Recapitalisations/Company Information/molecular diagnostics
20.12.2012


Not for distribution in the United States

Berlin, Germany, December 20, 2012 - Today the Executive Board of Epigenomics
AG, Berlin, Germany (Frankfurt Prime Standard: ECX; ISIN: DE000A1K0516), with
the approval of the Supervisory Board, has taken the decision to implement an
increase of the issued share capital by utilization of  authorised capital. The
capital increase shall be carried out by way of a rights issue against cash
contributions. It shall be structured in such a manner that the gross proceeds
generated under the capital increase will amount to up to just under
EUR5,000,000 in order to make use of the available exemption from the
publication of a prospectus under German securities laws.

In early January 2013, the Supervisory and Executive boards of the Company plan
to resolve the details of the capital increase, in particular the maximum number
of new shares and the subscription ratio, which will then be published by way of
an ad hoc announcement without undue delay. Publication of the subscription
offer and beginning and end of the subscribtion period will subsequently take
place in line with German market practice.

The new shares will first be offered to the shareholders of the Company. Shares
not taken up by sharesholders might subsequently be offered in a private
placement to institutional investors.

Epigenomics AG intends to use the net proceeds from the offering to finance its
current operations and to build and strengthen the distribution capacities for
its products.

- End of Ad hoc -

Disclaimer 

This publication is not an offer of any securities for sale or a solicitation of
an offer to purchase any securities. 

This document is not an offer of securities for sale or a solicitation of an
offer to purchase securities in the United States. The shares of Epigenomics AG
(the "Shares") have not been registered under the U.S. Securities Act of 1933,
as amended (the "Securities Act") and may not be offered or sold in the United
States unless registered under the Securities Act or pursuant to an exemption
from such registration. There will be no public offering of the Shares in the
United States and the Shares will not be registered under the Securities Act. 

Contact:

Epigenomics AG                          
Antje Zeise CIRO
Manager IR | PR 
Epigenomics AG 
Phone: +49 (0) 30 24345 386 
ir@epigenomics.com
www.epigenomics.com


Further inquiry note:
Antje Zeise | CIRO 
Manager IR/PR 
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


issuer:      Epigenomics AG
             Kleine Präsidentenstraße 1
             D-10178 Berlin
phone:       +49 30 24345-0
FAX:         +49 30 24345-555
mail:     ir@epigenomics.com
WWW:      http://www.epigenomics.com
sector:      Biotechnology
ISIN:        DE000A1K0516
indexes:     Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
             regulated dealing/prime standard: Frankfurt 
language:   English
 

 

 



Das könnte Sie auch interessieren: